SBIR/STTR Research Award

SBIR Phase I: High-Throughput AST Using Gradient-Based Microfluidic

Award identifier dd9d6c0cb51d252d4a529e45fcfd49bbf448ac1a263c2371d83faf34ed8d596fAwarding agency National Science Foundation

Award amount

$305,000

Program and phase

SBIR · Phase I

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
GIANT BioSystems Inc.
Proposal award date
2025-02-26
Contract end date
2026-02-28
UEI
FQZXTU2YRYK9
Solicitation number
NSF 24-579
Topic code
BM

Research abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to create a rapid point-of-care antimicrobial susceptibility testing (AST) kit that can be run on the same day the sample is taken. This will help physicians to utilize the best antibiotic at the optimal dosage sooner, reducing the number of exposures for antimicrobial resistance (AMR). Such infections are responsible for more than 2.8 million infections and 35,000 deaths annually in the U.S. The integration of the proposed platform with mobile devices for result interpretation ensures that it can be widely deployed, including in resource-limited settings and during emergencies. This adoptability is crucial for promptly responding to future pandemics and ensuring that even remote or underserved areas have access to advanced diagnostic capabilities. This project will help to reduce the economic burden associated with AMR ($20 billion/year) and infectious diseases ($41 billion/year). Once commercialized, the proposed platform is expected to promote better antibiotic stewardship, reducing antibiotic release into the environment. Antibiotics in plants and the food chain pose risks to human and animal health, and contribute to the spread of resistant bacteria, making infections harder to treat and increasing outbreak risk. This Small Business Innovation Research (SBIR) Phase I project will develop a novel microfluidic platform for rapid and precise AST. Current methods, such as broth microdilution and Kirby-Bauer disk diffusion, are limited by long turnaround times of 3-5 days. This delay leads to a postponement in adjusting antibiotics. Even emerging rapid diagnostic systems, while quicker, still require >20 hours to provide results, resulting in >4 doses of broad-spectrum antibiotics before precision adjustments can be made. The proposed platform generates actionable results within 6-9 hours from time of sample, as opposed to the conventional 3-5 days, ident

Technology keywords

Not reported

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.